The DOPPS Practice Monitor for US Dialysis Care: Potential Impact of Recent Guidelines and Regulatory Changes on Management of Mineral and Bone Disorder Among US Hemodialysis Patients  Francesca Tentori, MD, Douglas S. Fuller, MS, Friedrich K. Port, MD, MS, Brian A. Bieber, MPH, MS, Bruce M. Robinson, MD, MS, Ronald L. Pisoni, PhD, MS  American Journal of Kidney Diseases  Volume 63, Issue 5, Pages 851-854 (May 2014) DOI: 10.1053/j.ajkd.2014.02.003 Copyright © 2014 National Kidney Foundation, Inc. Terms and Conditions

Figure 1 Facility-reported upper levels of target ranges for markers of mineral and bone disorder, 2009-2012. Data reflect upper limits of targets reported by DOPPS (Dialysis Outcomes and Practice Patterns Study) medical directors for (top) serum parathyroid hormone, (middle) total serum calcium, and (bottom) serum phosphorus during DOPPS phases 4 (2009-2011) and 5 (2012). Conversion factors for units: calcium in mg/dL to mmol/L, ×0.2495; phosphorus in mg/dL to mmol/L, ×0.3229. American Journal of Kidney Diseases 2014 63, 851-854DOI: (10.1053/j.ajkd.2014.02.003) Copyright © 2014 National Kidney Foundation, Inc. Terms and Conditions

Figure 2 Mean mineral and bone disorder marker levels and proportions of patients above clinically relevant cutoff points. Values at each month are based on the most recent monthly value obtained within the prior 3 months for (top) serum parathyroid hormone (PTH) and most recent monthly values for (middle) total serum calcium and (bottom) serum phosphorus. Conversion factors for units: calcium in mg/dL to mmol/L, ×0.2495; phosphorus in mg/dL to mmol/L, ×0.3229. American Journal of Kidney Diseases 2014 63, 851-854DOI: (10.1053/j.ajkd.2014.02.003) Copyright © 2014 National Kidney Foundation, Inc. Terms and Conditions